Your browser is no longer supported. Please, upgrade your browser.
Settings
CRL Charles River Laboratories International, Inc. daily Stock Chart
CRL [NYSE]
Charles River Laboratories International, Inc.
Index- P/E30.11 EPS (ttm)3.79 Insider Own1.60% Shs Outstand47.45M Perf Week3.27%
Market Cap5.41B Forward P/E20.32 EPS next Y5.61 Insider Trans-17.01% Shs Float46.88M Perf Month7.59%
Income182.90M PEG2.77 EPS next Q1.22 Inst Own99.74% Short Float2.61% Perf Quarter14.42%
Sales1.81B P/S2.99 EPS this Y2.10% Inst Trans0.21% Short Ratio3.46 Perf Half Y30.08%
Book/sh20.25 P/B5.63 EPS next Y10.12% ROA6.70% Target Price109.18 Perf Year41.61%
Cash/sh2.95 P/C38.66 EPS next 5Y10.88% ROE20.70% 52W Range67.20 - 113.83 Perf YTD49.72%
Dividend- P/FCF22.62 EPS past 5Y7.50% ROI8.20% 52W High0.21% Beta0.93
Dividend %- Quick Ratio1.50 Sales past 5Y8.00% Gross Margin38.40% 52W Low69.75% ATR1.39
Employees11000 Current Ratio1.70 Sales Q/Q8.10% Oper. Margin15.40% RSI (14)79.84 Volatility1.19% 1.22%
OptionableYes Debt/Eq1.19 EPS Q/Q52.20% Profit Margin10.10% Rel Volume0.75 Prev Close112.92
ShortableYes LT Debt/Eq1.16 EarningsNov 09 BMO Payout0.00% Avg Volume352.84K Price114.07
Recom2.20 SMA205.07% SMA507.96% SMA20021.36% Volume265,098 Change1.02%
Sep-19-17Initiated RBC Capital Mkts Sector Perform $110
Dec-16-16Upgrade Goldman Sell → Neutral
Nov-30-16Upgrade Barclays Underweight → Equal Weight $65 → $77
Sep-06-16Downgrade UBS Neutral → Sell $83 → $78
Jun-21-16Initiated Credit Suisse Neutral $84
May-20-16Reiterated Barclays Underweight $60 → $65
Apr-26-16Initiated Gabelli & Co Buy $96
Jan-07-16Upgrade Wells Fargo Market Perform → Outperform
Oct-12-15Upgrade Wells Fargo Underperform → Market Perform
Jul-31-15Reiterated Deutsche Bank Hold $76 → $79
Jul-10-15Upgrade BofA/Merrill Neutral → Buy $76 → $83
Jul-10-15Downgrade Barclays Equal Weight → Underweight $60
May-04-15Upgrade Sun Trust Rbsn Humphrey Neutral → Buy $88
Apr-24-15Reiterated Barclays Equal Weight $55 → $60
Feb-12-15Reiterated Deutsche Bank Hold $63 → $77
Feb-13-14Reiterated Barclays Equal Weight $41 → $55
Nov-21-13Initiated Deutsche Bank Hold $55
Sep-17-13Initiated UBS Neutral $49
Jun-03-13Reiterated Barclays Equal Weight $38 → $41
May-02-13Reiterated ISI Group Neutral $45.50 → $44.50
Oct-16-17 08:04AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Oct-13-17 08:03AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Oct-12-17 04:30PM  Charles River Laboratories Changes the Date of Its Third-Quarter 2017 Earnings Release and Conference Call Business Wire
Oct-11-17 04:30PM  Charles River Laboratories Schedules Third-Quarter 2017 Earnings Release and Conference Call Business Wire
08:04AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Oct-10-17 08:03AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Oct-09-17 08:03AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Oct-06-17 08:03AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Oct-05-17 08:03AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Oct-02-17 08:01AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Sep-27-17 08:01AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Sep-25-17 08:01AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Sep-20-17 08:02AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Sep-18-17 08:02AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Sep-15-17 08:01AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Sep-14-17 08:02AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Sep-12-17 08:02AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
08:00AM  Charles River Research Models in Drug Discovery Award Presented to Sonia Vallabh and Eric Minikel of the Prion Alliance Business Wire
Sep-05-17 08:00AM  Charles River Laboratories to Present at September Investor Conferences Business Wire
Sep-01-17 07:20AM  Earnings Review and Free Research Report: Charles Rivers Q2 Results Outshined Market Expectations ACCESSWIRE
Aug-31-17 08:08AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Aug-30-17 08:03AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Aug-29-17 08:00AM  Distinguished Industry Leaders Join Lineup for Inaugural Charles River World Congress on Animal Models in Drug Discovery & Development Business Wire
Aug-24-17 03:09PM  ETFs with exposure to Charles River Laboratories International, Inc. : August 24, 2017 Capital Cube
Aug-23-17 08:02AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Aug-22-17 08:03AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Aug-18-17 12:30PM  Carl Data Solutions Announces Private Placement in Support of New Productivity Features for Applications GlobeNewswire
Aug-17-17 08:04AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Aug-15-17 08:22AM  Inaugural Charles River World Congress on Animal Models in Drug Discovery & Development to Explore Trends in Reverse Translational Medicine Business Wire
Aug-14-17 12:04PM  Charles River Laboratories International, Inc. :CRL-US: Earnings Analysis: Q2, 2017 By the Numbers : August 14, 2017 Capital Cube
Aug-12-17 10:30PM  Edited Transcript of CRL earnings conference call or presentation 9-Aug-17 12:30pm GMT Thomson Reuters StreetEvents
08:01AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Aug-11-17 08:01AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Aug-10-17 08:03AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Aug-09-17 10:19PM  Charles River beats Street 2Q forecasts Associated Press
08:41AM  Charles River Laboratories International, Inc. breached its 50 day moving average in a Bearish Manner : CRL-US : August 9, 2017 Capital Cube
08:01AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
07:00AM  Charles River Laboratories Announces Second-Quarter 2017 Results from Continuing Operations Business Wire
Aug-07-17 07:30AM  Charles River Laboratories Acquires Brains On-Line Business Wire
Jul-13-17 08:30AM  Charles River Laboratories Schedules Second-Quarter 2017 Earnings Release and Conference Call Business Wire
Jul-05-17 08:00AM  Charles River Laboratories Adds Martin Mackay, Ph.D. to Board of Directors Business Wire
Jun-05-17 04:45PM  Charles River Laboratories to Present at Jefferies Global Healthcare Conference Business Wire
Jun-02-17 06:47PM  Cramer's lightning round: I'm blessing this chipmaker for a quick trade CNBC
Jun-01-17 01:43PM  ETFs with exposure to Charles River Laboratories International, Inc. : June 1, 2017 Capital Cube
May-30-17 08:15AM  Post Earnings Coverage as Charles River Laboratories' Revenue Surged 25.6%, non-GAAP EPS Jumped 32% Accesswire
May-25-17 11:43AM  Which Stocks Are Showing Rising Relative Strength? Investor's Business Daily
11:40AM  Charles River Labs Re-Enters Buy Zone; Gets Stock Rating Upgrade Investor's Business Daily
May-23-17 09:29AM  Opening Bell, May 23, 2017 CNBC Videos
09:17AM  Today's Bell Ringer, May 23, 2017 CNBC Videos
May-16-17 01:35PM  Edited Transcript of CRL earnings conference call or presentation 10-May-17 12:30pm GMT Thomson Reuters StreetEvents
12:49PM  ETFs with exposure to Charles River Laboratories International, Inc. : May 16, 2017 Capital Cube
08:00AM  Charles River Laboratories Announces Updates to Oncology Business Business Wire
May-15-17 10:55AM  Charles River Laboratories International, Inc. :CRL-US: Earnings Analysis: Q1, 2017 By the Numbers : May 15, 2017 Capital Cube
May-12-17 12:35PM  Charles River shareholders reject PETA proposal on monkey research American City Business Journals
08:27AM  Charles River Laboratories International, Inc. breached its 50 day moving average in a Bearish Manner : CRL-US : May 12, 2017 Capital Cube
May-11-17 08:31PM  Edited Transcript of CRL earnings conference call or presentation 10-May-17 12:30pm GMT Thomson Reuters StreetEvents
May-10-17 07:10AM  Charles River beats Street 1Q forecasts Associated Press
07:00AM  Charles River Laboratories Announces First-Quarter 2017 Results from Continuing Operations Business Wire
May-09-17 09:58AM  Medical Services Stock Q1 Earnings on May 10: CRL, XON, INCR Zacks
May-05-17 04:26PM  4 Medical Stocks That Could Be Big Winners Next Week Benzinga
Apr-26-17 09:08AM  Charles River Laboratories International, Inc. breached its 50 day moving average in a Bearish Manner : CRL-US : April 26, 2017 Capital Cube
Apr-12-17 04:30PM  Charles River Laboratories Schedules First-Quarter 2017 Earnings Release and Conference Call Business Wire
01:22PM  Charles River Laboratories International, Inc. Value Analysis (NYSE:CRL) : April 12, 2017 Capital Cube
Apr-11-17 08:31AM  Charles River Laboratories International, Inc. breached its 50 day moving average in a Bearish Manner : CRL-US : April 11, 2017 Capital Cube
Apr-10-17 04:44PM  Parexel Is Discovering the Drugs of the Future TheStreet.com
Apr-05-17 08:00AM  Nimbus Therapeutics Enters into Strategic Partnership with Charles River Laboratories to Advance New Therapeutic Programs Business Wire
08:00AM  Nimbus Therapeutics Enters into Strategic Partnership with Charles River Laboratories to Advance New Therapeutic Programs
Apr-03-17 08:00AM  Charles River Laboratories Announces Launch of Triple-Immunodeficient Mouse Model for Oncology Research Business Wire
Mar-14-17 07:25AM  Charles River Labs settles with feds over NIH billing flap at bizjournals.com
07:25AM  Charles River Labs settles with feds over NIH billing flap American City Business Journals
Mar-13-17 05:55PM  Company to pay $1.8M to settle claims of overbilling
05:55PM  Company to pay $1.8M to settle claims of overbilling Associated Press
05:55PM  Company to pay $1.8M to settle claims of overbilling
08:00AM  Charles River Laboratories and Chiesi Farmaceutici SpA Announce Extension of Integrated Respiratory Drug Discovery Program Business Wire
Mar-06-17 08:00AM  Charles River Laboratories to Present at Raymond James and Barclays Conferences Business Wire
Feb-18-17 01:04PM  CHARLES RIVER LABORATORIES INTERNATIONAL INC Financials
Feb-16-17 12:28PM  Charles River Laboratories International, Inc. :CRL-US: Earnings Analysis: 2016 By the Numbers : February 16, 2017 Capital Cube
12:28PM  Charles River Laboratories International, Inc. :CRL-US: Earnings Analysis: 2016 By the Numbers : February 16, 2017
Feb-15-17 10:23AM  Charles River Laboratories International, Inc. :CRL-US: Earnings Analysis: Q4, 2016 By the Numbers : February 15, 2017
Feb-14-17 05:03PM  Edited Transcript of CRL earnings conference call or presentation 14-Feb-17 1:00pm GMT Thomson Reuters StreetEvents +7.86%
05:03PM  Edited Transcript of CRL earnings conference call or presentation 14-Feb-17 1:00pm GMT
08:00AM  Charles River Laboratories International Inc Earnings Call scheduled for 8:00 am ET today
07:07AM  Q4 2016 Charles River Laboratories International Inc Earnings Release - Before Market Open
07:01AM  CHARLES RIVER LABORATORIES INTERNATIONAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Finan
06:48AM  Charles River tops Street 4Q forecasts Associated Press
06:48AM  Charles River tops Street 4Q forecasts
06:30AM  Charles River Laboratories Announces Fourth-Quarter and Full-Year 2016 Results from Continuing Operations and Provides 2017 Guidance Business Wire
Feb-13-17 08:57AM  Healthcare Stock Q4 Earnings Slated for Feb 14: ESRX, CRL, Q
Feb-09-17 08:30AM  Charles River Laboratories Changes Time of Fourth-Quarter 2016 Earnings and 2017 Guidance Conference Call Business Wire
Jan-30-17 08:00AM  Charles River Laboratories Announces Progress Update for Collaboration with Moderna Therapeutics Business Wire
Jan-20-17 04:56PM  John Rogers Comments on Charles River Laboratories Intl
03:28PM  John Rogers' Ariel Fund 4th Quarter Commentary
Jan-19-17 04:30PM  Charles River Laboratories Schedules Fourth-Quarter 2016 Earnings and 2017 Guidance Release and Conference Call Business Wire
Jan-10-17 07:22AM  CHARLES RIVER LABORATORIES INTERNATIONAL INC Files SEC form 8-K, Results of Operations and Financial Condition
Jan-09-17 08:30AM  Charles River Laboratories to Present at J.P. Morgan Healthcare Conference Business Wire
Dec-26-16 07:07AM  Charles River Laboratories International, Inc. breached its 50 day moving average in a Bullish Manner : CRL-US : December 26, 2016
Dec-16-16 10:25AM  Charles River Laboratories International, Inc. Value Analysis (NYSE:CRL) : December 16, 2016
08:14AM  Analysts' Actions -- GE, Nordstrom, Coca-Cola, Eli Lilly and More
07:54AM  Charles River upgraded by Goldman
Dec-15-16 07:04AM  Charles River Laboratories International, Inc. breached its 50 day moving average in a Bullish Manner : CRL-US : December 15, 2016
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery and development services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily genetically and microbiologically defined purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening preclinical drug candidates comprising genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for identification of a druggable target through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, which comprise bioanalysis, pharmacokinetics, drug metabolism, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. This segment also offers specialized testing of biologics and devices that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free fertile chicken eggs and chickens used in the manufacture of live viruses. The company serves pharmaceutical and biotechnology companies, contract research organizations, agricultural and chemical companies, life science and veterinary medicine companies, contract manufacturing organizations, medical device companies, diagnostic and other commercial entities, hospitals, academic institutions, and government agencies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Molho DavideCorporate Executive VPOct 05Option Exercise76.676,165472,67122,714Oct 06 12:17 PM
JOHST DAVID PCorporate Executive VPOct 05Option Exercise40.4024,7591,000,264206,014Oct 06 12:21 PM
Molho DavideCorporate Executive VPOct 05Sale110.006,165678,15016,549Oct 06 12:17 PM
JOHST DAVID PCorporate Executive VPOct 05Sale110.0024,7592,723,490181,255Oct 06 12:21 PM
Molho DavideCorporate Executive VPSep 05Option Exercise74.9614,5391,089,83431,088Sep 07 08:50 AM
Molho DavideCorporate Executive VPSep 05Sale108.432,668289,29716,549Sep 07 08:53 AM
Molho DavideCorporate Executive VPSep 05Sale108.065,889636,34719,217Sep 07 08:51 AM
Molho DavideCorporate Executive VPSep 05Sale107.555,982643,37325,106Sep 07 08:50 AM
Barbo William DCorporate Executive VP & CCOAug 17Sale99.914,000399,63216,924Aug 21 06:42 AM
Smith David RossCorporate Executive VP & CFOAug 14Option Exercise76.121,24995,07412,920Aug 16 08:02 AM
Smith David RossCorporate Executive VP & CFOAug 14Sale67.102,552171,22811,671Aug 16 08:02 AM
MASSARO GEORGEDirectorJul 17Option Exercise43.394,030174,86218,731Jul 18 12:51 PM
MASSARO GEORGEDirectorJul 17Sale101.3820020,27614,701Jul 18 01:04 PM
MASSARO GEORGEDirectorJul 17Sale100.813,830386,10314,901Jul 18 12:51 PM
FOSTER JAMES CChairman, President and CEOJul 10Sale100.0250050,008336,178Jul 12 07:15 AM
FOSTER JAMES CChairman, President and CEOJul 10Sale99.305,720568,011336,678Jul 12 07:13 AM
FOSTER JAMES CChairman, President and CEOJul 10Sale99.079,264917,818342,398Jul 12 07:11 AM
FOSTER JAMES CChairman, President and CEOJul 10Sale98.929,516941,337351,662Jul 12 07:09 AM
Molho DavideCorporate Executive VPJun 22Option Exercise59.4110,948650,42127,497Jun 23 10:39 AM
FOSTER JAMES CChairman, President and CEOJun 22Option Exercise76.6743,1543,308,617404,332Jun 23 02:03 PM
Molho DavideCorporate Executive VPJun 22Sale100.0010,9481,094,80016,549Jun 23 10:39 AM
FOSTER JAMES CChairman, President and CEOJun 22Sale100.0043,1544,315,400361,178Jun 23 02:03 PM
Smith David RossCorporate Executive VP & CFOJun 08Option Exercise51.4594548,62014,203Jun 09 10:23 AM
Smith David RossCorporate Executive VP & CFOJun 08Sale95.0094589,77513,258Jun 09 10:23 AM
Molho DavideCorporate Executive VPMay 26Option Exercise49.8810,976547,49127,525May 31 06:57 AM
Molho DavideCorporate Executive VPMay 26Sale92.8410,9761,019,02216,549May 31 06:57 AM
Kochevar Deborah TurnerDirectorMay 12Option Exercise70.293,140220,71115,856May 16 11:01 AM
Kochevar Deborah TurnerDirectorMay 12Sale88.0330026,4088,486May 16 11:02 AM
Kochevar Deborah TurnerDirectorMay 12Sale87.937,070621,6408,786May 16 11:01 AM
MASSARO GEORGEDirectorMay 12Sale88.301,13099,78414,701May 15 03:26 PM
Molho DavideCorporate Executive VPMar 16Sale90.0011,7171,054,53016,549Mar 17 07:11 AM
Molho DavideCorporate Executive VPMar 15Option Exercise40.405,502222,28128,266Mar 17 07:11 AM
JOHST DAVID PCorporate Executive VPMar 10Option Exercise36.6241,9001,534,280223,155Mar 13 03:19 PM
Molho DavideCorporate Executive VPMar 10Sale89.713,191286,25447,017Mar 13 03:30 PM
JOHST DAVID PCorporate Executive VPMar 10Sale89.447,307653,540181,255Mar 13 03:21 PM
JOHST DAVID PCorporate Executive VPMar 10Sale89.0634,5933,080,932188,562Mar 13 03:19 PM
Barbo William DCorporate Executive VP & CCOMar 06Option Exercise65.8711,448754,09735,372Mar 07 03:47 PM
Barbo William DCorporate Executive VP & CCOMar 06Sale87.901,900167,01420,924Mar 07 04:09 PM
Barbo William DCorporate Executive VP & CCOMar 06Sale87.7812,5481,101,40922,824Mar 07 03:47 PM
Smith David RossCorporate EVP, CFO & CAOMar 03Option Exercise71.4511,640831,65125,135Mar 07 07:01 AM
Smith David RossCorporate EVP, CFO & CAOMar 03Sale88.123,890342,80513,495Mar 07 07:03 AM
Smith David RossCorporate EVP, CFO & CAOMar 03Sale87.947,750681,53117,385Mar 07 07:01 AM
BERTOLINI ROBERT JDirectorMar 01Option Exercise37.8111,990453,34232,140Mar 02 11:34 AM
BERTOLINI ROBERT JDirectorMar 01Sale88.006,735592,70220,150Mar 02 11:36 AM
BERTOLINI ROBERT JDirectorMar 01Sale87.535,255459,98826,885Mar 02 11:34 AM
FOSTER JAMES CChairman, President and CEOFeb 28Option Exercise59.4120,0711,192,418401,801Mar 01 03:34 PM
FOSTER JAMES CChairman, President and CEOFeb 28Sale87.315,038439,887391,853Mar 01 03:36 PM
FOSTER JAMES CChairman, President and CEOFeb 28Sale87.094,910427,615396,891Mar 01 03:34 PM
FOSTER JAMES CChairman, President and CEOFeb 28Sale88.481,270112,375381,730Mar 01 03:44 PM
FOSTER JAMES CChairman, President and CEOFeb 28Sale88.033,772332,064383,000Mar 01 03:42 PM
FOSTER JAMES CChairman, President and CEOFeb 28Sale87.615,081445,167386,772Mar 01 03:38 PM
FOSTER JAMES CChairman, President and CEOFeb 22Option Exercise40.4021,779879,872388,294Feb 24 02:50 PM
FOSTER JAMES CChairman, President and CEOFeb 22Sale88.223,404300,300366,515Feb 24 02:55 PM
FOSTER JAMES CChairman, President and CEOFeb 22Sale87.858,658760,562369,919Feb 24 02:53 PM
FOSTER JAMES CChairman, President and CEOFeb 22Sale87.649,717851,592378,577Feb 24 02:50 PM
MILNE GEORGE M JRDirectorFeb 14Option Exercise30.4410,710326,01239,240Feb 15 02:39 PM
MILNE GEORGE M JRDirectorFeb 14Sale86.5210,710926,62928,530Feb 15 02:39 PM
JOHST DAVID PCorporate Executive VPJan 30Option Exercise37.9213,950528,984174,696Feb 01 08:32 AM
JOHST DAVID PCorporate Executive VPJan 30Sale78.0013,9501,088,100160,746Feb 01 08:32 AM
WALLMAN RICHARD FDirectorDec 13Option Exercise33.934,540154,04220,990Dec 14 09:55 AM
CHUBB STEPHEN DDirectorDec 02Option Exercise30.4410,710326,01230,849Dec 05 02:59 PM
CHUBB STEPHEN DDirectorDec 02Sale71.574,564326,64526,285Dec 05 02:59 PM
REESE C RICHARDDirectorNov 28Option Exercise30.4410,710326,01244,943Nov 29 08:43 AM
REESE C RICHARDDirectorNov 28Sale71.934,539326,48540,404Nov 29 08:43 AM